SCYNEXIS (SCYX) Expected to Announce Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is anticipated to release its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect SCYNEXIS to post earnings of ($0.21) per share and revenue of $0.1480 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 14, 2025 at 3:00 PM ET.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09. SCYNEXIS had a negative net margin of 599.05% and a negative return on equity of 43.04%. The company had revenue of $1.36 million during the quarter, compared to analysts’ expectations of $0.15 million.

SCYNEXIS Stock Down 3.9%

NASDAQ:SCYX opened at $0.66 on Monday. SCYNEXIS has a 52 week low of $0.65 and a 52 week high of $1.49. The firm has a 50 day moving average of $0.88 and a 200 day moving average of $0.84. The stock has a market capitalization of $27.67 million, a price-to-earnings ratio of -1.65 and a beta of 1.68.

Analysts Set New Price Targets

A number of brokerages have issued reports on SCYX. Guggenheim cut their price target on shares of SCYNEXIS from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Weiss Ratings restated a “sell (e+)” rating on shares of SCYNEXIS in a research note on Tuesday, October 14th. Finally, Wall Street Zen upgraded shares of SCYNEXIS to a “hold” rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, SCYNEXIS presently has an average rating of “Hold” and an average target price of $3.00.

Institutional Trading of SCYNEXIS

A hedge fund recently raised its stake in SCYNEXIS stock. Bridgeway Capital Management LLC lifted its holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) by 4.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 368,180 shares of the company’s stock after acquiring an additional 14,689 shares during the quarter. Bridgeway Capital Management LLC owned 0.94% of SCYNEXIS worth $248,000 as of its most recent SEC filing. 54.37% of the stock is currently owned by institutional investors.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.